Author:
Meillon-Garcia Luis Antonio,Demichelis-Gómez Roberta
Publisher
Springer Science and Business Media LLC
Reference73 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.
2. • Vaughn JE, Shankaran V, Walter RB. Trends in clinical benefits and costs of novel therapeutics in AML: at what price does progress come? Curr Hematol Malignancy Rep. 2019;14:171–8. https://doi.org/10.1007/s11899-019-00510-2. This study analyzes the complexities of assessing costs versus benefits of AML treatment, emphasizing novel agents.
3. Noone AM, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975–2015. Bethesda, MD: National Cancer Institute; 2018. based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Available from: https://seer.cancer.gov/csr/1975_2015/.
4. Bewersdorf JP, Shallis RM, Wang R, Huntington SF, Perreault S, Ma X, et al. Healthcare expenses for treatment of acute myeloid leukemia. Expert Rev Hematol. 2019;12:641–50. https://doi.org/10.1080/17474086.2019.1627869.
5. Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, et al. Health care use by older adults with acute myeloid leukemia at the end of life. J Clin Oncol. 2017;35:3417–24. https://doi.org/10.1200/JCO.2017.72.7149.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献